Characterizing Treatment Patterns and Healthcare Use in Patients and Subgroups with Chronic Inflammatory...

Area of Science:

• Neurology
• Immunology
• Clinical Research

Background:

• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare autoimmune peripheral nervous system disorder.
• A significant portion of CIDP patients exhibit refractory or partial responses to standard treatments.
• Limited data exists on the disease burden for CIDP patients with suboptimal treatment responses.

Purpose of the Study:

• To analyze the demographics, clinical characteristics, and healthcare resource utilization of CIDP patients in the US.
• To focus on patients who switched therapies within two years of initiating first-line treatment (LOT1).

Main Methods:

• Retrospective analysis of integrated de-identified data from the Optum Market Clarity dataset (2008-2020).
• Inclusion of adult patients diagnosed with CIDP.
• Identification of patients initiating first-line treatment (LOT1) and subsequent second-line treatment (LOT2).

Main Results:

• The study included 1942 treated CIDP patients; 31% switched to LOT2 within two years of LOT1 initiation.
• The median time to switch from LOT1 to LOT2 was 5.6 months.
• Patients switching treatments experienced higher annual healthcare visits (45.3) compared to those who did not (35.3).

Conclusions:

• Approximately one-third of CIDP patients switch treatments within two years, suggesting limited efficacy of initial therapies.
• Frequent treatment changes and increased healthcare encounters indicate substantial unmet needs in CIDP management.
• The findings underscore the need for improved and more effective treatment strategies for CIDP patients.